Embera adds $4.5 million in Series A cash

Embera NeuroTherapeutics says it has garnered $4.5 million in a continuation of its Series A financing. The money will go to development of new treatments for smoking cessation and other addictions. "This investment will enable us to complete preclinical development for EMB-001 and to bring this drug candidate entirely through a Phase I safety study," said CEO Bob Linke. Release

Suggested Articles

A Roche compound that was designed to treat rheumatoid arthritis could improve the heart's ability to repair itself, a Vanderbilt team found.

After a whirlwind year and two quick-fire raises, cancer startup Black Diamond Therapeutics has nabbed Yumanity, Merck KGaA and SR One veterans to help head up…

In this week's EuroBiotech Report, Lundbeck inks $2 billion Alder buyout, Euro biotechs raise cash and blast rocks Russian smallpox lab.